Danny Rischin
Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
Harrington K, Burtness B, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Lin J, Gumuscu B, Swaby R, Rischin D. Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study. J Clin Oncol 2022:JCO2102508.
11.10.2022Pembrolizumab With or Without Chemotherapy in Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Updated Results of the Phase III KEYNOTE-048 Study.
11.10.2022J Clin Oncol 2022:JCO2102508
Harrington Kevin J, Burtness Barbara, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Lin Jianxin, Gumuscu Burak, Swaby Ramona F, Rischin Danny
Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
Rischin D, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Ishak W, Hong R, Mendoza R, Jia L, Chirovsky D, Norquist J, Jin F, Burtness B. Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048. Oral Oncol 2022; 128:105815.
02.04.2022Pembrolizumab alone or with chemotherapy for recurrent or metastatic head and neck squamous cell carcinoma: Health-related quality-of-life results from KEYNOTE-048.
02.04.2022Oral Oncol 2022; 128:105815
Rischin Danny, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Ishak Wan Zamaniah Wan, Hong Ruey-Long, Mendoza René Gonzalez, Jia Liyi, Chirovsky Diana, Norquist Josephine, Jin Fan, Burtness Barbara
Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
Burtness B, Rischin D, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Brana I, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Ge J, Swaby R, Gumuscu B, Harrington K. Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score. J Clin Oncol 2022; 40:2321-2332.
25.03.2022Pembrolizumab Alone or With Chemotherapy for Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma in KEYNOTE-048: Subgroup Analysis by Programmed Death Ligand-1 Combined Positive Score.
25.03.2022J Clin Oncol 2022; 40:2321-2332
Burtness Barbara, Rischin Danny, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Brana Irene, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Ge Joy, Swaby Ramona F, Gumuscu Burak, Harrington Kevin J
Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
Burtness B, Harrington K, Greil R, Soulières D, Tahara M, de Castro G, Psyrri A, Basté N, Neupane P, Bratland Å, Fuereder T, Hughes B, Mesia R, Ngamphaiboon N, Rordorf T, Wan Ishak W, Hong R, González Mendoza R, Roy A, Zhang Y, Gumuscu B, Cheng J, Jin F, Rischin D. Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study. Lancet 2019; 394:1915-1928.
01.11.2019Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study.
01.11.2019Lancet 2019; 394:1915-1928
Burtness Barbara, Harrington Kevin J, Greil Richard, Soulières Denis, Tahara Makoto, de Castro Gilberto, Psyrri Amanda, Basté Neus, Neupane Prakash, Bratland Åse, Fuereder Thorsten, Hughes Brett G M, Mesia Ricard, Ngamphaiboon Nuttapong, Rordorf Tamara, Wan Ishak Wan Zamaniah, Hong Ruey-Long, González Mendoza René, Roy Ananya, Zhang Yayan, Gumuscu Burak, Cheng Jonathan D, Jin Fan, Rischin Danny
Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
Au-Yeung G, Etemadmoghadam D, Drapkin R, Karst A, Rischin D, Mileshkin L, Pearson R, Cullinane C, Aziz D, Lackovic K, Jarman K, Mitchell C, Azar W, Winder F, Bowtell D. Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition. Clin Cancer Res 2017; 23:1862-1874.
23.09.2017Selective Targeting of Cyclin E1-Amplified High-Grade Serous Ovarian Cancer by Cyclin-Dependent Kinase 2 and AKT Inhibition
23.09.2017Clin Cancer Res 2017; 23:1862-1874
Au-Yeung George, Etemadmoghadam Dariush, Drapkin Ronny, Karst Alison M, Rischin Danny, Mileshkin Linda, Pearson Richard B, Cullinane Carleen, Aziz Diar, Lackovic Kurt, Jarman Kate E, Mitchell Chris, Azar Walid J, Winder Franziska, Bowtell David D L